Mercaptopurine

Generic Name
Mercaptopurine
Brand Names
Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
Drug Type
Small Molecule
Chemical Formula
C5H4N4S
CAS Number
50-44-2
Unique Ingredient Identifier
PKK6MUZ20G
Background

An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

Indication

For remission induction and maintenance therapy of acute lymphatic leukemia.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Associated Therapies
-
Clinical Trials
Related News

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

First Posted Date
2023-07-25
Last Posted Date
2023-09-08
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
180
Registration Number
NCT05959720
Locations
🇧🇷

Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

First Posted Date
2023-05-08
Last Posted Date
2024-11-25
Lead Sponsor
Tanja Andrea Gruber
Target Recruit Count
90
Registration Number
NCT05848687
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 22 locations

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

First Posted Date
2022-12-21
Last Posted Date
2023-03-03
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
100
Registration Number
NCT05660473
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

First Posted Date
2022-12-09
Last Posted Date
2024-07-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT05645718
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2022-08-18
Last Posted Date
2022-08-18
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
10
Registration Number
NCT05506332
Locations
🇧🇪

University Hospital Antwerp, Edegem, Antwerp, Belgium

🇧🇪

AZ Delta, Roeselare, West Vlaanderen, Belgium

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

First Posted Date
2022-03-31
Last Posted Date
2024-08-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
66
Registration Number
NCT05303792
Locations
🇺🇸

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

🇺🇸

Marshfield Medical Center - Weston, Weston, Wisconsin, United States

🇺🇸

Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States

and more 61 locations

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

First Posted Date
2022-01-14
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
35
Registration Number
NCT05192889
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

First Posted Date
2021-12-15
Last Posted Date
2024-10-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
24
Registration Number
NCT05157971
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date
2021-09-02
Last Posted Date
2024-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT05032183
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2020-09-14
Last Posted Date
2024-10-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
300
Registration Number
NCT04546399
Locations
🇺🇸

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

🇺🇸

Corewell Health Dearborn Hospital, Dearborn, Michigan, United States

🇺🇸

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States

and more 200 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy